Phase II Trial of Bevacizumab Plus Etoposide for Patients With Recurrent Malignant Glioma

Inclusion Criteria:

- Pts have confirmed diagnosis of recurrent/progressive WHO gr III & IV MG

- Age >18 rs

- Interval of >4 wks since prior surgery

- Interval of >4 wks since prior XRT/chemo, unless there is unequivocal evidence of
progressive disease & pts have recovered from all anticipated toxicity of most recent
therapy;

- Karnofsky performance status score >60

- Hematocrit >29 percent, ANC >1,500 cells/microliter, platelets >100,000
cells/microliter

- Serum creatinine <1.5 mg/dl, BUN <25 mg/dl, serum SGOT & bilirubin <1.5 x ULN

- For pts on corticosteroids, they have been on astable dose for 1wk prior to entry

- Signed informed consent approved by IRB prior to pt entry

- If sexually active, pts must agree to take contraceptive measures for duration of
treatments.

Exclusion Criteria:

- Prior therapy w either bevacizumab/etoposide

- >3 prior recurrences

- Pregnancy/breast feeding

- Co-medication w immuno-suppressive agents other than corticosteroids including but
not limited to cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil

- Evidence of CNS hemorrhage on baseline MRI on CT scan

- Pts who require therapeutic anti-coagulation

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection requiring IV antibiotics & psychiatric illness/social situations that would
limit compliance w study requirements, or disorders associated w significant
immunocompromised state

- Pts w another primary malignancy that has required treatment